View Post

Alisertib-Based Combo Improves Survival Outcomes in Ovarian, Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jessica Skarzynski From: curetoday.com For some time now, paclitaxel has been considered standard of care in the treatment of patients with platinum-resistant ovarian cancer; however, recent research has shown the addition of the investigational drug alisertib to a paclitaxel regimen demonstrated promising activity in patients with recurrent ovarian cancer or advanced breast cancer. In the JAMA Oncology study, the …

View Post

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

In In The News by Barbara Jacoby

Source: esmo.org From: news-medical.net Treatment with the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study …

View Post

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

In Clinical Trials by Barbara Jacoby

Source: upmc.com From: news-medical.net Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the …

View Post

How Do I Know If My Advanced Breast Cancer Therapy Is Working?

In In The News by Barbara Jacoby

From: healthline.com Knowing if your current therapy treatment is truly doing everything it can to beat your breast cancer is, well, difficult to say the least. Here are some things to think about or consider. What are the symptoms of metastatic cancer? It’s not always easy to tell if cancer is progressing, despite treatment. That’s because it doesn’t always cause …

View Post

Lilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer

In In The News by Barbara Jacoby

From: PR Newswire Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. This additional FDA approval …

View Post

90% of cancer deaths happen because it spreads. Researchers found clue to stopping it

In In The News by Barbara Jacoby

By: Teresa Welsh From: miamiherald.com Researchers from Johns Hopkins University have found a clue to stopping cancer metastasis, the spreading of the disease responsible for 90 percent of cancer deaths. A team led by Hasini Jayatilaka and Denis Wirtz discovered that a biochemical signaling process causes cancer cells to break away from an original tumor and spread to other areas …

View Post

Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer

In In The News by Barbara Jacoby

From: PR Newswire — Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack — Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay — Approval comes less than two months after Kisqali received US FDA approval  Novartis announced today that the US Food and Drug Administration (FDA) has approved the …